Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02017704 · ClinicalTrials.gov registry record · Phase 2
Chemoradiation or Brachytherapy for Rectal Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02017704 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 9 participants.
The verdict
NCT02017704, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the bowel (rectum).
Interventions
- PROCEDURE Surgery
- RADIATION IMRT (intensity modulated radiation therapy)
- DRUG FOLFOX6
- RADIATION Endo-HDR (if randomized to this arm)
- DRUG capecitabine and IMRT (if randomized to this arm)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-06-12 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02017704
The ClinicalTrials.gov registry entry for NCT02017704 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Surgery is the first listed.
NCT02017704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02017704 about?
NCT02017704 is a clinical study titled "Chemoradiation or Brachytherapy for Rectal Cancer". This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the bowel (rectum).
What is the current status of trial NCT02017704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2014-06-12. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT02017704?
The interventions under investigation include: Surgery (PROCEDURE), IMRT (intensity modulated radiation therapy) (RADIATION), FOLFOX6 (DRUG), Endo-HDR (if randomized to this arm) (RADIATION), capecitabine and IMRT (if randomized to this arm) (DRUG).
Who is sponsoring clinical trial NCT02017704?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.